TPSA及FPSA比在前列腺癌与良性前列腺增生鉴别诊断中的应用  

Application of TPSA and FPSA Ratio in Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia

作　　者：许敏烨 李志广 林明恩[3] XU Minye;LI Zhiguang;Lin Ming'en(School of Medicine,Shantou University,Shantou,Guangdong 515041;Southern Medical University Shenzhen Hospital,Shenzhen,Guangdong 518100;School of Medicine,Shantou University The First Affiliated Hospital,Shantou,Guangdong 515000)

机构地区：[1]汕头大学医学院,广东汕头515041 [2]南方医科大学深圳医院,广东深圳518100 [3]汕头大学医学院第一附属医院,广东汕头515000

出　　处：《智慧健康》2024年第8期153-156,160,共5页Smart Healthcare

摘　　要：目的观察前列腺癌与良性前列腺增生鉴别诊断中血清前列腺特异抗原(TPSA)与游离前列腺特异抗原(FPSA)的价值。方法对2022年1—12月本院接诊的前列腺癌患者(前列腺癌组)和良性前列腺增生患者(良性前列腺增生组)各35例进行研究,对所有患者行微离子酶免疫标记法进行TPSA及FPSA测定,比较两组TPSA、FPSA水平,统计组间不同年龄血清TPSA浓度,观察两组TPSA、FPSA水平诊断准确率。对比不同前列腺体积和PSAD诊断值下BHP与PCa诊断符合率统计。结果(1)两组TPSA水平、F/T值比较,前列腺癌组高于良性前列腺增生组,差异有统计学意义(P<0.05);两组FPSA水平比较,前列腺癌组高于良性前列腺增生组,差异无统计学意义(P>0.05);(2)前列腺癌组66~75岁、>75岁患者TPSA水平高于良性前列腺增生组,差异有统计学意义(P<0.05);(3)前列腺癌组诊断准确率高于良性前列腺增生组,差异无统计学意义(P>0.05);(4)前列腺体积<45mL,BPH诊断符合率低于PCa,差异有统计学意义(P<0.05);(5)PSAD<1.00ng/mL·cm^(3),BPH诊断符合率高于PCa,差异有统计学意义(P<0.05);PSAD<1.50ng/mL·cm^(3),BPH诊断符合率高于PCa,差异有统计学意义(P<0.05)。结论对前列腺癌与良性前列腺增生疾病进行诊断,患者TPSA水平均呈现出升高现象,为进一步提升临床诊断准确率,综合分析患者TPSA水平与F/T值至关重要,应用价值显著。Objective To observe value of serum prostate specific antigen(TPSA)and free pre prostate specific antigen(FPSA)in differential diagnosis of prostate cancer and benign prostatic hyperplasia.Methods The paper chose 35 patients with prostate cancer and 35 patients with benign prostatic hyperplasia in our hospital from January 2022 to December 2022,measured TPSA and FPSA levels with microzyme immunolabeling.Levels of TPSA and FPSA between groups were compared,and serum TPSA concentrations at different ages were statistically analyzed.Diagnostic accuracy of TPSA and FPSA levels in both groups were observed,diagnostic accuracy of BHP and PCa under different prostate volumes and PSAD diagnostic values was compared.Results(1)Comparison showed,TPSA levels and F/T values in prostate cancer group were higher than benign prostatic hyperplasia group,with statistical difference of P<0.05.Comparison of FPSA levels between two groups showed,those of prostate cancer group were higher than benign prostatic hyperplasia group,with P>0.05,there was no statistically significant difference.(2)TPSA levels aged 66-75 and over 75 in prostate cancer group were higher than benign prostatic hyperplasia group,with statistical difference of P<0.05.(3)Diagnostic accuracy of prostate cancer group was higher than benign prostatic hyperplasia group,with P>0.05,with no statistical difference.(4)Prostate volume<45mL,diagnostic accuracy of BPH was lower than PCa,P<0.05,with statistical difference.(5)PSAD<1.00 ng/mL·cm^(3),diagnostic accuracy of BPH was higher than PCa,P<0.05,with statistical difference.PSAD<1.50ng/m L·cm^(3),diagnostic accuracy of BPH was higher than PCa,P<0.05,with statistical difference.Conclusion TPSA levels increase for patients with prostate cancer and benign prostatic hyperplasia.To further improve the accuracy of clinical diagnosis,comprehensive analysis of TPSA levels and F/T values is crucial,which has significant application value.

关 键 词：TPSA FPSA比 前列腺癌 良性前列腺增生 鉴别诊断 

分 类 号：R737.25[医药卫生—肿瘤] R697.3[医药卫生—临床医学]